Advertisement

Prediabetes defined by the International Expert Committee as a risk for development of glomerular hyperfiltration

  • Iori Kawata
  • Tomomichi Koshi
  • Kazuko Hirabayashi
  • Hideo Koike
  • Yuka Sato
  • Koh Yamashita
  • Tomomasa Oguchi
  • Toru AizawaEmail author
Original Article
  • 24 Downloads

Abstract

Aims

To clarify if prediabetes defined by the International Expert Committee (PrediabetesIEC) and/or the American Diabetes Society (PrediabetesADA) is a risk for incident glomerular hyperfiltration (GH).

Methods

24,524 health examinees without diabetes, chronic kidney disease (CKD), GH and antihypertensive treatment at baseline, and repeated examinations at least twice during a mean of 5.3 years were retrospectively analysed. Diabetes was defined as fasting plasma glucose (FPG) ≥ 7.0 mmol/L and/or HbA1c ≥ 47 mmol/mol, CKD by estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2 and/or dipstick-positive proteinuria, and GH by upper 95th eGFR in the Japanese adults. PrediabetesIEC was diagnosed by “HbA1c 42–46 mmol/mol and/or FPG 6.1–6.9 mmol/L”, PrediabetesADA by “HbA1c 39–46 mmol/mol and/or FPG 5.6–6.9 mmol/L”, PrediabetesADA−IEC for the condition met the ADA but not the IEC prediabetes definition, and the ADA-normal glucose regulation (NGRADA) by both HbA1c and FPG lower than PrediabetesADA. Risk of PrediabetesIEC and PrediabetesADA for incident GH was examined by multivariate Cox proportional hazards model with seven covariates and probability of incident GH was calculated on the basis of it.

Results

PrediabetesIEC was a significant risk for incident GH [adjusted HR 1.91, 95% CI 1.32–2.71] but PrediabetesADA was not [adjusted HR 1.22, 95% CI 0.93–1.61]. The mean (SD) probability of incident GH was 2.3 (4.5)%, 1.0 (2.3)% and 1.0 (2.4)% for PrediabetesIEC, PrediabetesADA−IEC and NGRADA, respectively: the former was significantly larger than the latter two which were not significantly different from each other.

Conclusions

PrediabetesIEC was an independent risk for incident GH.

Keywords

Prediabetes Glomerular hyperfiltration IEC ADA 

Notes

Acknowledgements

The authors thank Drs. Hisashi Noma and Mitsuhiko Noda for their constructive comments.

Compliance with ethical standards

Conflict of interest

All Authors declare that they have no conflict of interest.

Informed consent

Informed consent for anonymous use of clinical data has been obtained.

Human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the responsible committee of human experimentation (institutional and national) and with the 1975 Helsinki declaration, as revised in 2008.

References

  1. 1.
    Christiansen JS (1985) Glomerular hyperfiltration in diabetes mellitus. Diabet Med 2:235–239CrossRefGoogle Scholar
  2. 2.
    Sun ZJ, Yang YC, Wu JS, Wang MC, Chang CJ, Lu FH (2016) Increased risk of glomerular hyperfiltration in subjects with impaired glucose tolerance and newly diagnosed diabetes. Nephrol Dial Transpl 31:1295–1301CrossRefGoogle Scholar
  3. 3.
    Rodriguez-Poncelas A, Coll-de-Tuero G, Blanch J, Comas-Cufí M, Saez M, Barceló MA (2018) Prediabetes is associated with glomerular hyperfiltration in a European Mediterranean cohort study. J Nephrol 31:743–749CrossRefGoogle Scholar
  4. 4.
    Melsom T, Schei J, Stefansson VT et al (2016) Prediabetes and risk of glomerular hyperfiltration and albuminuria in the general nondiabetic population: a prospective cohort study. Am J Kidney Dis 67:841–850CrossRefGoogle Scholar
  5. 5.
    Okada R, Yasuda Y, Tsushita K, Wakai K, Hamajima N, Matsuo S (2012) Glomerular hyperfiltration in prediabetes and prehypertension. Nephrol Dial Transpl 27:1821–1825CrossRefGoogle Scholar
  6. 6.
    Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG (2009) Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52:691–697CrossRefGoogle Scholar
  7. 7.
    Park M, Yoon E, Lim YH, Kim H, Choi J, Yoon HJ (2015) Renal hyperfiltration as a novel marker of all-cause mortality. J Am Soc Nephrol 26:1426–1433CrossRefGoogle Scholar
  8. 8.
    International Expert Committee (2009) International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32:1327–1334CrossRefGoogle Scholar
  9. 9.
    American Diabetes Association (2014) Diagnosis and classification of diabetes mellitus. Diabetes Care 37:S81–S90CrossRefGoogle Scholar
  10. 10.
    Inker LA, Astor BC, Fox CH et al (2014) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 63:713–735CrossRefGoogle Scholar
  11. 11.
    Matsuo S, Imai E, Horio M et al (2009) Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992CrossRefGoogle Scholar
  12. 12.
    Paulmichl K, Hatunic M, Højlund K et al (2016) Beta-JUDO Investigators; RISC Investigators. Modification and validation of the triglyceride-to-HDL cholesterol ratio as a surrogate of insulin sensitivity in white juveniles and adults without diabetes mellitus: the single point insulin sensitivity estimator (SPISE). Clin Chem 62:1211–1219CrossRefGoogle Scholar
  13. 13.
    Sagesaka H, Sato Y, Someya Y et al (2018) Type 2 diabetes: when does it start? J Endocr Soc 2:476–484CrossRefGoogle Scholar
  14. 14.
    Hirakawa Y, Ninomiya T, Mukai N et al (2012) Association between glucose tolerance level and cancer death in a general Japanese population: the Hisayama Study. Am J Epidemiol 176:856–864CrossRefGoogle Scholar
  15. 15.
    Hanefeld M, Sulk S, Helbig M, Thomas A, Köhler C (2014) Differences in glycemic variability between normoglycemic and prediabetic subjects. J Diabetes Sci Technol 8:286–290CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2019

Authors and Affiliations

  • Iori Kawata
    • 1
  • Tomomichi Koshi
    • 1
  • Kazuko Hirabayashi
    • 2
  • Hideo Koike
    • 2
  • Yuka Sato
    • 1
  • Koh Yamashita
    • 1
  • Tomomasa Oguchi
    • 3
  • Toru Aizawa
    • 1
    Email author
  1. 1.Diabetes CentreAizawa HospitalMatsumotoJapan
  2. 2.Health CentreAizawa HospitalMatsumotoJapan
  3. 3.Kidney Disease and Dialysis CentreAizawa HospitalMatsumotoJapan

Personalised recommendations